Ophthalmic lesions in neonatal foals evaluated for nonophthalmic disease at referral hospitals

Abstract

Ophthalmic lesions were detected in 55.7% of neonatal foals with systemic disease. Acquired ophthalmic disease was more commonly detected than congenital ophthalmic disease. Foals with sepsis were more likely to have uveitis than were foals without sepsis. A complete ophthalmic examination is indicated in neonatal foals evaluated for systemic disease.

Surgical correction of congenital entropion in related Boer goat kids using a combination Hotz‐Celsus and lateral eyelid wedge resection procedure

“…The clinical appearance of these cases was similar to previous descriptions of entropion in cattle, sheep, horses, and small animals . Two goats in this study had significant corneal stromal ulcerative defects as a secondary complication to their entropion consistent with previous reports . The goats in this study were affected prior to 1 month of age suggesting the condition may have been congenital.…”

“…Entropion is a well‐recognized veterinary ophthalmic abnormality diagnosed in dogs, cats, horses, sheep, cattle, and pigs . It most commonly occurs in sheep and dogs .…”

“…It most commonly occurs in sheep and dogs . Congenital entropion is considered a frequent occurrence in sheep, but it has also been reported in several other domestic animal species . In sheep, it is typically bilateral and limited to the lower eyelid .…”

Microvascular Complications and Diabetic Retinopathy: Recent Advances and Future Implications

“…Various kinase inhibitors have been investigated for the simultaneous inhibition of both VEGF and PDGF receptors for the treatment of ocular neovascularization [73,74]. A PEGylated aptamer, E10030 selectively inhibits PDGF-β and stimulates striping of pericytes from the endothelial cells [75]. It improves sensitivity of mature vasculature for anti-VEGF treatment.…”

“…Therefore, simultaneous administration of anti-VEGF agents along with E10030 may inhibit CNV. In fact, in Phase I clinical trials, 90% of the subjects have observed CNV regression when treated with ranibizumab and E10030, relative to 10% of the patients treated with ranibizumab alone [75,76]. A Phase II clinical study is currently under progress [205].…”